Get the latest news, insights, and market updates on ASMB (Assembly Biosciences, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Assembly Biosciences: Q2 Earnings Snapshot
ASMB) on Wednesday reported a loss of $10.2 million in its second quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.33. The biotech drug developer posted revenue of $9.6 million in the period. Aug 6, 2025 - $ASMB
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Further pharmacological assessment to be conducted in parallel with Phase 2 preparation – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics Aug 6, 2025 - $ASMB
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
– On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179 – – Positive topline data reported for Phase 1b study of ABI-4334, a next-generation highly potent capsid assembly modulator candidate, in participants with chronic hepatitis B virus (HBV) – – Interim data, including a biomarker for target engagement, reported from Phase 1a study Aug 6, 2025 - $ASMB
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates – – Preclinical data and U.S. genital herpes prevalence and treatment patterns also highlighted – – Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 – SOUTH SAN FRANCISCO, Calif., July 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB Jul 26, 2025 - $ASMB
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.